Clinical Trial Update: Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/2 clinical trial evaluating an autologous hapten-modified vaccine in patients with stage III or IV melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Autologous hapten-modified vaccine

Snippet

Sponsor: AVAX Technologies | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED